Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

Pilatus Biosciences Inc. earns FDA Orphan Drug Designation for PLT012, targeting liver and intrahepatic bile duct cancer

Pilatus Biosciences Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its leading molecule, PLT012, for treating liver and intrahepatic bile duct cancer (HCC/ICCA). Achieved in November...

UroMems Appoints Former Axonics Executive Rinda Sama to Board of Directors

implementing lean operations and compliant quality systems that helped to pave the way for Food and Drug Administration (FDA) approval and the recent acquisition of Axonics by Boston Scientific. Prior to Axonics, Sama was the director of operations...

Leqembi® approved in Mexico

(sBLA) for less frequent intravenous maintenance dosing was submitted to the U.S. Food and Drug Administration (FDA) in March 2024, which was accepted in June 2024. In October 2024, the rolling submission of a Biologics License Application (BLA)...

Phanes Therapeutics' PT217 receives FDA Fast Track Designation for neuroendocrine prostate cancer (NEPC)

on innovative drug discovery and development in oncology, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PT217 for the treatment of patients with metastatic de novo or treatment-emergent...

SciTech Development reveals promising Phase 1A trial results for T-cell non-Hodgkin lymphoma therapy

the trial, as we work toward bringing a new therapeutic option to oncology patients." Trial Design and Advancements: The FDA approved the Phase 1a accelerated dose-escalation design based on extensive research, prior clinical testing, and the...

Neurophet gains FDA 510(k) clearance for Neurophet AQUA, advancing multiple sclerosis analysis with AI-driven precision

brain disease, announced on the "Neurophet AQUA", has obtained 510(k) clearance from U.S. Food and Drug Administration (FDA) for its newly integrated multiple sclerosis (MS) analysis functionality. The initial clearance, secured in May last year,...

Hanmi Pharmaceutical and Beijing Hanmi advance clinical trials for BH3120, their co-developed next-generation cancer immunotherapy

Hanmi obtained approval from both the Korean Ministry of Food and Drug Safety and the U.S. Food and Drug Administration (FDA) to modify the Phase 1 trial plan to evaluate BH3120 in combination with KEYTRUDA. Full-scale clinical development is...

A Korea University study identifies mitochondrial dysfunction as a key factor in cognitive and metabolic impairments, offering insights into potential treatments

the clinical potential of this study "Similar to the first gene editing technology-based treatment that received FDA approval last year, I would like to see approval for a treatment based on mitochondrial gene editing technology for mitochondrial...

ResQ Pharma receives PDUFA date for LipidRescue™, potentially the first FDA-approved treatment for Local Anesthetic Systemic Toxicity (LAST)

become a widely available, standardized treatment for a dangerous and potentially fatal condition. As we await potential FDA review and approval, and prepare to launch the LipidRescue Kit, I'm very thankful to the many physicians, researchers,...

Bracco Diagnostics Inc. reaches one million injections milestone with its MRI agent, VUEWAY® (gadopiclenol)

Imaging S.p.A., a leading global company in the diagnostic imaging business, is proud to announce that its most recently FDA-approved magnetic resonance imaging (MRI) agent, VUEWAY® (gadopiclenol) solution for injection, has reached over one...

SystImmune secures FDA clearance for BL-M17D1 IND in advanced solid tumors

Inc (SystImmune), a clinical-stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for BL-M17D1, an antibody-drug conjugate (ADC) with a novel linker and...

GC Biopharma and Novelty Nobility sign an R&D agreement to develop therapies for geographic atrophy

approximately 1.5 million people are affected by this condition. Last year, the first treatment for GA was approved by the FDA in the US. However, the drug demonstrated limited efficacy by slowing the progression of GA without restoring previously...

The U.S. FDA provides positive guidance on the Phase III trial of 64Cu-SAR-bisPSMA for recurrent prostate cancer.

diagnostic in patients with BCR of prostate cancer following a successful end of phase meeting with the U.S. FDA. The trial, named AMPLIFY (64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants with Biochemical Recurrence...

FDA approves Bristol Myers Squibb's COBENFY™, a novel treatment for adult schizophrenia.

Bristol Myers Squibb (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) has approved COBENFY™ (xanomeline and trospium chloride), an oral medication for the treatment of schizophrenia in adults. COBENFY represents the first new...

EydisBio receives FDA Orphan Drug Designation for its TAK1 inhibitor to treat systemic sclerosis.

EydisBio, Inc. is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to EYD-001, its highly selective and potent, orally bioavailable TAK1 inhibitor for the treatment of systemic sclerosis....

nuBioAge, nuHx, and Marius Pharmaceuticals launch a collaborative GLP-1 comparison study in male patients.

center, nuHx, and Marius Pharmaceuticals, the company behind KYZATREX® (testosterone undecanoate) CIII capsules, an FDA-approved oral testosterone treatment for men. Together, they aim to conduct a pioneering study that will measure the impact of...

ChromaDex expands its pharmaceutical-grade Niagen® IV and injection offerings to more leading wellness clinics.

follows the successful debut of limited quantities of Niagen IV and injections in select clinics earlier last month. U.S. FDA-registered 503B outsourcing facility, Wells Pharma of Houston, will compound and distribute pharmaceutical-grade Niagen,...

Zydus announces an exclusive licensing and supply agreement for two Gadolinium-based MRI injectable contrast agents in the U.S

development and manufacturing as well as CDMO services. Viwit has three integrated product R&D centers, three cGMP US FDA inspected production facilities. By continuously improving the level, depth and scope of innovation, Viwit makes every effort...

City of Hope and BRC treat first patient with BRC-001 in a breast cancer care trial.

City of Hope professor of breast surgery and lead investigator of the trial. "We hope this work will yield innovative, FDA-approved therapies to help patients complete their lifesaving treatments." The clinical trial entitled "High Cannabidiol...

Bloomage 2024 Mid-Year Report: International raw material sales exceed domestic Chinese market sales for the first time

HACCP and FSSC22000 for food-grade materials—while achieving certifications from global regulatory bodies including the FDA, MFDS, and PMDA. This commitment to quality enables Bloomage to serve diverse markets with confidence, continually driving...